Dark Mode
COVID-19 Vaccine Company Stock Performance
Stock & Market Data
Tags and Keywords
Trusted By
"No reviews yet"
Free
About
Stock data tracking the performance of major COVID-19 vaccine development companies between 2019 and 2021. This product offers detailed insights into how stock valuations reacted to pandemic-related developments, serving as a critical resource for financial and public health investigations. The inclusion of 2019 data is specifically motivated by the IPO timing of several involved companies.
Brief Description
This collection captures daily stock market activity for key pharmaceutical entities heavily involved in the COVID-19 vaccine effort. It provides the necessary metrics for analysts to perform detailed studies on corporate performance influenced by the global health crisis. The data allows for sophisticated analysis of market volatility and returns for these biopharma stocks across the critical period leading up to and spanning the early stages of the pandemic response. The expectation is that this information will inspire further investigation into company performance under significant market pressure.
Columns
The data file contains 49 columns, recording date and various stock metrics for eight specific companies.
Key metrics recorded for each company include:
- High (The highest price traded during the period)
- Low (The lowest price traded during the period)
- Open (The opening price)
- Close (The closing price)
- Volume (Total number of shares traded)
- Adj Close (Adjusted closing price)
Companies covered are: BioNTech, Moderna, Johnson & Johnson, Inovio Pharmaceuticals, Sinovac, Sinopharm, Novavax, and Astrazeneca (Oxford).
Distribution
The data is structured as a CSV file titled
vaccine stocks.csv, with a file size of 358.44 kB. The structure consists of 49 columns. There are 505 valid records across the time series data for each company's key stock indicators. The data is expected to be updated on a weekly basis.Usage
This data set is suitable for various quantitative analyses, including:
- Examining correlations between vaccine regulatory milestones and stock price movements.
- Developing algorithmic trading strategies focused on the biotechnology and pharmaceutical sectors during periods of rapid global change.
- Conducting historical simulations to model financial reactions to public health emergencies.
- Assessing the overall market impact of the pandemic on firms critical to the medical response.
Coverage
The temporal scope of the data ranges from 10 October 2019 up to 11 October 2021. The selection of 2019 as a starting point reflects the fact that some companies had just completed their Initial Public Offering (IPO) around that date. The scope focuses on specific global companies known for their involvement in COVID-19 vaccine production.
License
CC0: Public Domain
Who Can Use It
- Financial Researchers: To evaluate investment returns and risks associated with pandemic-era biopharma stocks.
- Policy Analysts: To understand the economic incentives and outcomes for private companies responding to global health challenges.
- Data Science Professionals: For training time-series models focused on predicting equity price fluctuations based on macroeconomic and health-related inputs.
Dataset Name Suggestions
- COVID-19 Vaccine Company Stock Performance 2019-2021
- Biopharma Equity Market Data: Pandemic Influence
- Global Vaccine Stock Metrics
Attributes
Original Data Source: COVID-19 Vaccine Company Stock Performance
QUALITY